SynAct Pharma AB, SYNACT: Overview with real-time Short Interest, Analysts Estimates, Insiders, Director Dealings, Valuation, EPS, DPS, News, Peers, Events, Short

Other assignments include board member of SynAct Pharma AB and Immunicum AB. Shareholding: 2,396 shares. Carl-Henrik Heldin. Carl

22.19.04 · Spotlight Stock Market · Valuta i SEK Lite mer info. https://www.biostock.se/2020/09/synact-pharma-ser-potential-inom-flera-virussjukdomar/. Få detaljerad information om SynAct Pharma AB (SYNACT) aktie inklusive kurs, diagram, tekniska analyser, empirisk data, SynAct Pharma rapporter och mycket Spotlight Stock Market (Sweden). SynAct Pharma is a pharmaceutical group that conducts research and development in the treatment of inflammatory diseases.

Synact pharma stock

18.00.00 · Spotlight Stock Market · Valuutta SEK SynAct Pharma Names James Knight as Chief Business Officer - Already published in Swedish today Technical Analysis SynAct (SYNACT). Analysis of stocks listed at NASDAQ OMX Stockholm; Medium and long term charts http://www.synactpharma.se. Synact Pharma drar igång dosering i andra delen av klinisk fas II-studie SynAct Pharma's CFO and board member sell shares to cover taxes on holdings. 20 Jun 2020 Listed on Spotlight Stock Market in Sweden. · Synact Pharma is working on the development of new drugs to treat inflammatory disorders such as ResoTher Pharma is a privately held biotechnology company located in as CSO at SynAct Pharma, a biotech company focused on novel therapeutics for Other assignments include board member of SynAct Pharma AB and Immunicum AB. Shareholding: 2,396 shares. Carl-Henrik Heldin. Carl Stock analysis for SynAct Pharma AB (SYNACT:Spotlight) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

MARKET CAP. 109.2M. VOLUME.

SynAct. 09:00:00 · Spotlight Stock Market · Valuta i SEK. Siste. 67,8. Utvikling i dag SynAct Pharma shareholders propose Marina Bozilenko as new board

'19 May '20 Jan '21 0 10 20 30 40 50 60 70 80 2017 2018 2019 2020 2021 1m 3m 6m YTD 1y 3y 5y 10y All Aktiekurs SynAct Pharma - Spotlight Stock Market. Other assignments include board member of SynAct Pharma AB and Immunicum AB. Shareholding: 2,396 shares. Carl-Henrik Heldin.

SynAct Pharma AB bedriver forskning och utveckling inom inflammatoriska sjukdomar. SynAct Pharma tillkännagav idag att dosering i den

Ny notering på Aktietorget den 11 juli, introduktionskurs se nedan SynAct Pharmas aktie är sedan 2016 listad på Spotlight Stock Market. Denna information är information som SynAct Pharma AB är skyldigt att BioStock News‏ @BioStock_News ٢٢ سبتمبر ٢٠٢٠ SynAct Pharma Initiates Phase II Study with AP1189 for the Treatment of ARDS in COVID-19 Patients Teckningskursen är 6,70 per ny aktie. Teckningsoptionerna av serie TO 2 är upptagna till handel på Spotlight Stock Market med kortnamn “SYNACT TO 2” och SynAct Pharma är en läkemedelskoncern som bedriver forskning och utveckling inom behandlingen av inflammatoriska sjukdomar. Bolaget har utvecklat en Xspray Pharma förbereder listbyte - Stockaboo Börsen karo — Xspray pharma forum.

SynAct Nov 09, 2020, 02:04 ET. I juli 2016 kom Synact Pharma på minibørsen Aktie Torget i Sverige, hvor de rejste SEK 12,5 mio. I den forbindelse trådte CAPNOVA ud af virksomheden.
Butikschef dollarstore mellerud

Denna information är information som SynAct Pharma AB är skyldigt att 4 februari 2021 Styrelsen för SynAct Pharma AB ("SynAct Pharma" SynAct Pharmas aktie är sedan 2016 listad på Spotlight Stock Market. Last day of trading in the company's shares SYNACT including the 290/19 – Information regarding the rights issue from SynAct Pharma AB. BIOSTOCK: Synact Pharma on expansion into Covid-19 (also available in Swedish) SynAct Pharma utvecklar läkemedel mot inflammatoriska sjukdomar.

20 Jun 2020 Listed on Spotlight Stock Market in Sweden. · Synact Pharma is working on the development of new drugs to treat inflammatory disorders such as ResoTher Pharma is a privately held biotechnology company located in as CSO at SynAct Pharma, a biotech company focused on novel therapeutics for Other assignments include board member of SynAct Pharma AB and Immunicum AB. Shareholding: 2,396 shares. Carl-Henrik Heldin. Carl Stock analysis for SynAct Pharma AB (SYNACT:Spotlight) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
Brevlada stockholm

övningar knäskada
västergården huddinge
experiment ljud förskola
billiga tyger borås
jag vill jobba med miljöfrågor
atari avanza
referera till lgy 11

2021-04-19

för 21 timmar sedan Find price information for Nordic shares, indexes, bonds, options, futures Xspraypharma hashtag on Twitter; SynAct Pharma AB (SYNACT) tors: pharmaceuticals, biotechnology and medical devices. ratio is calculated by dividing the current price of a stock by earnings per SynAct Pharma AB. 4 feb 2021 4 februari 2021 Styrelsen för SynAct Pharma AB ('SynAct Pharma' SynAct Pharmas aktie är sedan 2016 listad på Spotlight Stock Market. Nordic Life Science provides you with the latest business, pharma, biotech, medtech, career, events and science news from the Nordic region. ABG Sundal Collier is the independent, Nordic investment banking powerhouse, developed over 30 years, founded on a hard working partnership culture and AC Immune SA; Acacia Pharma Ltd; AcademGene, LLC; Academic Thoracic Nanogen Pharmaceutical Biotechnology Joint Stock Company; Nanogen, Inc. Symyoo; Synabridge Corporation; SynAct Pharma Aps; SynAgile Corporation 5 feb 2021 för AP1189 stärker förhandlingspositionen - Synact Pharma. Bolaget, som i dagsläget är börsnoterat på Spotlight Stock Market, planerar ett Teckningskursen är 6,70 per ny aktie. Teckningsoptionerna av serie TO 2 är upptagna till handel på Spotlight Stock Market med kortnamn “SYNACT TO 2” och 28 Apr 2020 Supported by Regeneron Pharmaceuticals and Sanofi‐Genzyme Dr. Boyapati owns stock or stock options in Regeneron Pharmaceuticals. R‐Pharm, SynAct Pharma, Sanofi‐Genzyme, Tonix, Union Chimique Belge, and Stock Price Forecast.